A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Xerox and Vortran Medical Partnering Allows for Mass Produce of Disposable Ventilators

The two companies expect to work together to quickly respond to the shortage of critical ventilation equipment necessary to support patients breathing. Assuming a stable supply of essential parts, the companies will be rapidly scaling up production from approximately 40,000 ventilators in April to between 150,000 and 200,000 ventilators a month by June. Together, Xerox and Vortran could produce as many as 1 million ventilators in the coming months.

While the GO2Vent is not a replacement for ventilators found in intensive care units (ICUs), it is widely used in emergency situations, inter-hospital transport and MRIs. Given the shortage of ICU-grade ventilators, medical professionals are utilizing tools like this and other technology to support patients who do not yet or no longer need an ICU-level breathing device, which can be freed up for another patient.

“Our smartest minds met (virtually) with Vortran’s smartest minds and figured out how to mass-produce this critical technology,” said John Visentin, vice chairman and chief executive officer, Xerox. “We want to help make sure doctors, nurses and paramedics on the frontlines have the resources they need to help the rising number of patients with COVID-19.”

Xerox plans to manufacture these FDA-approved ventilators and APM-Plus devices at its facility outside of Rochester, NY, where the company was founded and maintains a large presence. Vortran will continue to manufacture ventilators at its current facility in Sacramento, CA.

“The partnership with Xerox has one clear goal – to help save as many lives as possible. With Vortran’s proven technology and Xerox’s ability to hyper-scale manufacturing, we believe we can supply healthcare providers as many as 1 million ventilators in the coming months,” said Vortran Co-founder and CEO, Gordon A. Wong, M.D. “For all of us, this will be the most important thing we ever do.”

Vortran’s GO2Vent was designed for emergency use, natural disasters and disease outbreaks such as the COVID-19 pandemic. A gas-operated, disposable ventilator that can be set-up within minutes and discarded after use by a single patient, it provides support via a secure airway and can be operated on a compressor, oxygen or air with a minimum of 10 liters per minute flow rates.

The GO2Vent can provide continuous ventilatory support for up to 30 days and operates independently of Vortran’s APM-Plus. The APM-Plus is a battery-operated, portable device that connects to a GO2Vent and provides enhanced monitoring of patient status and key respiratory parameters. Given the need to confirm key supplies, the companies are actively assessing how quickly production can ramp for the APM-Plus devices.

In addition to scaling up production of the GO2Vent and APM-Plus, Xerox and Vortran expect to compile and analyze data and feedback from healthcare professionals on the frontlines of the battle against COVID-19 in order to design and mass-produce external, in-line modifications that can be added to the GO2Vent to expand the potential applications of this life-saving equipment.

Both Xerox and Vortran will distribute the products.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy